The "rule of 5" has become a mainstay of decision-making in the pharmaceutical industry as well as in nonindustrial (academic and institutional) drug development. However the authors of the original paper never intended for "double cutoffs" to preclude development of new drug leads for parasitic diseases.
No takes yet. Share an insight, caveat, or question.
McKerrow et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: